Ascendis Pharma A/S Income Statement Analysis

Revenue, earnings, and profit margins in millions EUR

Scroll to see more
Ascendis Pharma A/S income statement - Annual data in millions EUR
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Jan 2023Dec 2021Dec 2020
Revenue & Gross Profit
Revenue363.64266.7251.177.786.95
Cost of Revenue44.2644.4012.143.520.00
Gross Profit319.38222.3239.044.266.95
Operating Expenses
Research & Development307.00413.45379.62295.87260.90
Selling, General & Administrative291.14264.41221.23160.1876.67
Operating Expenses598.15677.86600.85456.05337.57
Operating Income-278.76-455.54-561.81-451.79-330.62
Other Income/Expense
Interest Income14.3616.867.430.691.81
Interest Expense-65.5044.07-30.683.911.92
Other Income/Expense3.873.74-15.48-15.90-88.45
Income
Income Before Tax-373.24-474.14-577.82-380.09-419.17
Income Tax Expense4.847.305.38-0.37-0.22
Net Income-378.08-481.45-583.19-379.72-418.96
Net Income - Continuous Operations-378.08-481.45-583.19-383.580.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-273.83-411.17-544.30-368.61-407.81
EBIT-278.76-430.08-561.81-384.00-417.26
Depreciation & Amortization4.945.6217.51-10.969.45
Earnings Per Share
Basic EPS-7.00-9.00-10.00-7.00-8.00
Diluted EPS-7.00-9.00-10.00-7.00-8.00
Basic Shares Outstanding57.8956.2956.0754.7750.62
Diluted Shares Outstanding57.8956.2956.0754.7750.62